“The Tafenoquine for Babesiosis Expanded Access clinical study may strengthen that hope in a patient population that has few treatment options today. We are pleased to be leading the way in ...

“The promise shown by tafenoquine in treating relapsing babesiosis can certainly give patients and physicians reason for hope and optimism,” said Geoff Dow, PhD, chief executive officer of 60 ...

announced the approval of an Investigational Review Board (IRB) for a Phase II clinical study aimed at evaluating the efficacy and safety of tafenoquine, marketed as ARAKODA®, for treating ...

Physicians or patients who wish to participate in the 60 Degrees Pharmaceuticals Tafenoquine for Babesiosis Expanded Access clinical study are encouraged to visit the Company’s website for ...

British scientists are infecting a group of volunteers with a type of malaria that can cause relapses years after contracting ...

(NASDAQ: SXTP; SXTPW) (“60 Degrees Pharmaceuticals” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that the first patient has ...

However, the hypnozoiticidal efficacy of current drugs like primaquine and tafenoquine cannot be directly assessed due to the undetectable nature of hypnozoites. Researchers conducted a retrospective ...